| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3266408 | Digestive and Liver Disease | 2007 | 4 Pages |
Abstract
Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
A. Lauro, A. Amaduzzi, A. Dazzi, G. Ercolani, C. Zanfi, L. Golfieri, G.L. Grazi, M. Vivarelli, M. Cescon, G. Varotti, M. Del Gaudio, M. Ravaioli, A. Siniscalchi, S. Faenza, A. D'Errico, M. Di Simone, L. Pironi, A.D. Pinna,